Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)

被引：0
|
作者：
Naohiro Okano
Chigusa Morizane
Shogo Nomura
Hideaki Takahashi
Hidetaka Tsumura
Hironaga Satake
Nobumasa Mizuno
Kunihiro Tsuji
Kazuhiko Shioji
Akinori Asagi
Kohichiroh Yasui
Sho Kitagawa
Tomomi Kashiwada
Atsushi Ishiguro
Masashi Kanai
Makoto Ueno
Takashi Ogura
Satoshi Shimizu
Kazutoshi Tobimatsu
Masayo Motoya
Koji Nakashima
Masafumi Ikeda
Takuji Okusaka
Junji Furuse
机构：
[1] Kyorin University Faculty of Medicine,Department of Medical Oncology
[2] National Cancer Center Hospital,Department of Hepatobiliary and Pancreatic Oncology
[3] National Cancer Center,Biostatistics Division, Center for Research Administration and Support
[4] National Cancer Center Hospital East,Department of Hepatobiliary and Pancreatic Oncology
[5] Hyogo Cancer Center,Department of Gastroenterology
[6] Kobe City Medical Center General Hospital,Department of Medical Oncology
[7] Aichi Cancer Center Hospital,Department of Gastroenterology
[8] Ishikawa Prefectural Central Hospital,Department of Gastroenterology
[9] Niigata Cancer Center Hospital,Department of Internal Medicine
[10] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[11] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology
[12] Sapporo Kosei General Hospital,Department of Gastroenterology
[13] Saga University,Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine
[14] Teine Keijinkai Hospital,Department of Medical Oncology
[15] Kyoto University,Department of Medical Oncology, Graduate School of Medicine
[16] Kanagawa Cancer Center,Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division
[17] St. Marianna University School of Medicine,Department of Clinical Oncology
[18] Saitama Cancer Center,Department of Gastroenterology
[19] Kobe University Graduate School of Medicine,Division of Gastroenterology, Department of Internal Medicine
[20] Sapporo Medical University School of Medicine,Department of Gastroenterology and Hepatology
[21] University of Miyazaki Hospital,Department of Clinical Oncology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pancreatic cancer; Gemcitabine; Oxaliplatin; Platinum compounds;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1835 / 1843
页数：8
相关论文
共 50 条
  • [21] Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study
    Song, Huiyeon
    Jung, Yoon Suk
    Tran, Thi Xuan Mai
    Moon, Chang Mo
    Park, Boyoung
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (05) : 950 - 957
  • [22] Phase II study of gemcitabine in patients with metastatic breast cancer
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Pearce, P
    Iglesias, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 664 - 664
  • [23] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
    Hong Suk Song
    Young Rok Do
    Heung Moon Chang
    Min Hee Ryu
    Kyung Hee Lee
    Yeul Hong Kim
    Dae Sik Hong
    Jae Yong Cho
    Kyoung Eun Lee
    Si Young Kim
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 763 - 768
  • [24] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
    Song, Hong Suk
    Do, Young Rok
    Chang, Heung Moon
    Ryu, Min Hee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Hong, Dae Sik
    Cho, Jae Yong
    Lee, Kyoung Eun
    Kim, Si Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 763 - 768
  • [25] A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
    Choi, Jong Gwon
    Seo, Jae Hong
    Oh, Sang Cheul
    Choi, Chul Won
    Kim, Jun Suk
    CANCER RESEARCH AND TREATMENT, 2012, 44 (02): : 127 - 132
  • [26] Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer
    Kindler, HL
    Friberg, G
    Singh, DA
    Locker, G
    Nattam, S
    Kozloff, M
    Taber, DA
    Karrison, T
    Dachman, A
    Stadler, WM
    Vokes, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8033 - 8040
  • [27] Family history of breast cancer as a risk factor for ovarian cancer in a prospective study
    Kazerouni, Neely
    Greene, Mark H.
    Lacey, James V., Jr.
    Mink, Pamela J.
    Schairer, Catherine
    CANCER, 2006, 107 (05) : 1075 - 1083
  • [28] Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer
    Stoll, Susanna
    Unger, Sheila
    Azzarello-Burri, Silvia
    Chappuis, Pierre
    Graffeo, Rossella
    Pichert, Gabriella
    Roethlisberger, Benno
    Taban, Francois
    Riniker, Salome
    SWISS MEDICAL WEEKLY, 2021, 151
  • [29] Gemcitabine combined with oxaliplatin (GEMOX) in pretreated metastatic breast cancer : A phase II study
    Altavilla, Giuseppe
    Caristi, Nicola
    Buemi, Barbara
    Marabello, Grazia
    Pettineo, Giuseppe
    Leone, Anna
    Montalto, Erika
    Scarfo, Paola
    ANNALS OF ONCOLOGY, 2005, 16 : 16 - 16
  • [30] Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study
    Kullmann, F.
    Hollerbach, S.
    Dollinger, M. M.
    Harder, J.
    Fuchs, M.
    Messmann, H.
    Trojan, J.
    Gaebele, E.
    Hinke, A.
    Hollerbach, C.
    Endlicher, E.
    BRITISH JOURNAL OF CANCER, 2009, 100 (07) : 1032 - 1036
12345